Quarterly report pursuant to Section 13 or 15(d)

Revenue - Narrative (Details)

v3.10.0.1
Revenue - Narrative (Details) - USD ($)
Feb. 08, 2018
Jun. 30, 2018
Dec. 31, 2017
Deferred Revenue Arrangement [Line Items]      
Current deferred revenues   $ 44,598,000 $ 37,153,000
Non-current deferred revenue   54,336,000 $ 46,542,000
Seattle Genetics | License and Collaboration Agreement      
Deferred Revenue Arrangement [Line Items]      
Upfront fees received $ 30,000,000    
Estimated reimbursements for research, development and manufacturing services 4,900,000    
Maximum tiered royalties on net sales $ 1,200,000,000    
Period after effective date agreements may be terminated 12 months    
Advance notice period for contract termination 90 days    
Allocable arrangement consideration $ 34,900,000    
Current deferred revenues   9,300,000  
Non-current deferred revenue   $ 16,700,000  
Seattle Genetics | License and Collaboration Agreement | Program Pivotal Study Initiated      
Deferred Revenue Arrangement [Line Items]      
Advance notice period for contract termination 180 days    
Seattle Genetics | License and Collaboration Agreement | Material Breach of Contract      
Deferred Revenue Arrangement [Line Items]      
Advance notice period for contract termination 90 days    
Seattle Genetics | License and Collaboration Agreement | Material Breach of Contract due to Diligence Obligations      
Deferred Revenue Arrangement [Line Items]      
Advance notice period for contract termination 90 days